OncLive | Updates in Hematology Oncology OncLive Bendamustine was approved in 2008 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen as well as for the treatment of chronic lymphocytic ... |
